Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Versartis Announces Publication of Preclinical Data for Once Monthly Human Growth Hormone Treatment in Journal of Pharmaceutical Sciences
– Phase I Clinical Data to be Presented Later this Month at ENDO 2012 –
View HTML
Toggle Summary Journal of Clinical Endocrinology & Metabolism Publishes Positive Versartis Phase I Data
– VRS-317 is Versartis’ Proprietary Long-Acting Growth Hormone Treatment –
View HTML
Toggle Summary Keith Lui Joins Versartis to Lead Global Marketing Efforts
Versartis Strengthens Leadership Team to Prepare for Commercialization of VRS-317
View HTML
Toggle Summary Paul Westberg Joins Versartis as Senior Vice President, Business Development
- Focus on Transactions for Novel Therapeutics –
View HTML
Toggle Summary Positive Results from Versartis Phase 1 Clinical Study of Once Monthly Human Growth Hormone Treatment Presented at ENDO 2012
– Positive Data Support Initiation of Next Study of VRS-317 –
View HTML
Toggle Summary SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes AMSTERDAM, August 17 - SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel
View HTML
Toggle Summary Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan
Teijin's regulatory and commercial infrastructure ideally suited to capitalize on somavaratan, which is positioned to be the first potential long-acting form of recombinant growth hormone (rhGH) to enter the Japanese market Teijin to receive exclusive license to commercialize and further develop
View HTML
Toggle Summary US FDA Grants Orphan Drug Designation to Versartis’ Treatment for Growth Hormone Deficiency
US FDA Grants Orphan Drug Designation to Versartis’ Treatment for Growth Hormone Deficiency Redwood City, CA – December 18, 2013 – Versartis, Inc., an endocrine-focused biopharmaceutical company, has received US Food and Drug Administration (FDA) orphan drug designation for its product candidate
View HTML
Toggle Summary Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology
MENLO PARK, Calif. , Aug. 4, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317) a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that
View HTML
Toggle Summary Versartis Announces Agenda and Event Details for Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency (GHD)
MENLO PARK, Calif. , Sept. 8, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML